Report of a second serious adverse event in a clinical trial of gene therapy for X-linked severe combined immune deficiency (X-SCID). Position of the European Society of Gene Therapy (ESGT).
Gansbacher
Bernd
B
ESGT Central Office Institutür Experimentelle Onkologie und Therapieforschung Technische Universität München Ismaninger Str. 22 81675 Munich, Germany.
D002675:Child, Preschool; D005060:Europe; D015316:Genetic Therapy / Q000009:adverse effects* / Q000941:ethics; D006801:Humans; D007223:Infant; D016511:Severe Combined Immunodeficiency / Q000628:therapy*